Nasal Mucosa Drug Supply Device Companies

Medtronic receives FDA approval for its Rhinostat Plus delivery system new device offers improved dosage control and medication stability for nasal sprays, potentially enhancing treatment efficacy and patient comfort.

Aptar Pharma introduces a novel nasal spray pump with integrated dose counter technology helps patients track their medication usage and ensure adherence to treatment regimens.

GlaxoSmithKline launches a new nasal corticosteroid spray with a unique applicator innovation aims to improve drug targeting and reduce side effects by delivering medication directly to affected areas in the nasal mucosa.

Catalent acquires Aptar Pharma's Dosage Forms & Delivery Systems business move strengthens Catalent's offerings in nasal drug delivery devices, providing wider access to their innovative technologies.

Pfizer partners with 3M to develop next-generation nasal delivery systems collaboration focuses on creating smart devices with integrated sensors and monitoring capabilities, enabling personalized drug delivery and improved data collection.

Boehringer Ingelheim collaborates with a start-up on a novel nasal vaccine delivery platform partnership aims to leverage advancements in nasal mucosal immunization for developing more effective and efficient vaccines.

List of Nasal Mucosa Drug Supply Device Key Companies in the Market

• GSK plc (UK)


• AstraZeneca (UK)


• Pfizer, Inc (US)


• Becton, Dickinson, and Company (US)


• Reddy's Laboratories (India)


• Cadila Pharmaceuticals Ltd (India)


• F. Ascher & Company, Inc (US)


• Douglas Pharmaceuticals Ltd (New Zealand)


• ENT Technologies Pty. Ltd (Australia)


• NAVEH Pharma Ltd (Israel)